- PN: B115596
45x Ab-conjugated beads (S4P9 - Human CA15-3 Ab-bead). PN: B115596A. One vial containing 100 µL of anti-human CA15-3 conjugated to AimPlex Bead S4P9.
25x Biotin-detection Ab (Human CA15-3 Biotin-dAb). PN: B115596B. One vial containing 100 µL of biotinylated anti-human CA15-3.
Lyophilized Standard Mix - Human CA15-3. PN: B115596S. One vial containing lyophilized CA15-3.
STORAGE: 2-8 C in the dark.
IMPORTANT: Sodium azide forms explosive compounds with heavy metals. These products contain <0.05% (w/w) azide which with repeated contact with lead and copper commonly found in plumbing drains may result in the buildup of shock sensitive compounds. Dispose in accordance with regulations from your institute.
APPLICATION: Optimal antibody pair and antigen standard for assaying human Human CA15-3/MUC1. To be used in conjunction with the AimPlex NR Basic Kit (PN: P100001) and a diluent kit. Refer to the AimPlex Multiplex Immunoassay User Manual and kit inserts for the assay procedure.
For Research Use Only. Not for use in diagnostic procedures.
Sample types: Cell culture supernatant, serum, plasma, bodily fluid and tissue/cell lysate
Sensitivity (LOD): < 20 mUnit/mL
LLOQ: < 50 Unit/mL
ULOQ: > 10,000 Unit/mL
Standard dose recovery: 70-130%
Intra-assay CV: < 10%
Inter-assay CV: < 20%
Sample volume: 15 µL/test
CA15-3 (Cancer Antigen 15-3) is a tumor marker used to monitor certain cancers, especially breast cancer. It is found on the surface of many types of cancer cells and shed into the blood stream. It is used to monitor advanced, i.e. metastatic, cancer. Elevated CA15-3, in conjunction with alkaline phosphatase (ALP), was found to be associated with an increased chance of early recurrence in breast cancer.
1. Keshaviah et al. “CA15-3 and alkaline phosphatase as predictors for breast cancer recurrence: a combined analysis of seven International Breast Cancer Study Group trials.” 18 (4): 701 - Annals of Oncology. 2007
2. Chu WG1, Ryu DW1. “Clinical significance of serum CA15-3 as a prognostic parameter during follow-up periods in patients with breast cancer.” Ann Surg Treat Res. 2016 Feb;90(2):57-63. doi: 10.4174/astr.2016.90.2.57. Epub 2015 Jan 28.